DVA Share Price | DaVita, Inc. Stock Analysis & Recommendation

Q: Is DaVita, Inc. overvalued or undervalued?

As of 12 May 2025, the valuation grade for DaVita, Inc. has moved from attractive to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 10, an EV to EBITDA ratio of 7.83, and a PEG ratio of 0.75, which suggests that despite a low P/E, the overall valuation does not support a favorable investment case given the risks involved.In comparison to its peers, DaVita's P/E ratio of 9.71 is significantly lower than Encompass Health Corp. at 20.94 and The Ensign Group, Inc. at 32.46, both of which are rated attractive. Additionally, the company's return performance has lagged behind the S&P 500, with a year-to-date return of -12.92% compared to the index's 12.22%, and a one-year return of -20.18% versus 17.14%. This underperformance reinforces the notion that DaVita, Inc. is currently overvalued in the market.

Q: Is DaVita, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for DaVita, Inc. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. Bollinger Bands confirm a bearish trend on both weekly and monthly time frames. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, while the Dow Theory indicates a mildly bearish trend on the weekly with no trend on the monthly. The OBV is mildly bearish across both time frames.In terms of performance, DaVita has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -12.92% versus the S&P 500's 12.22%, and a one-year return of -20.18% compared to the S&P 500's 17.14%. Overall, the current technical stance is bearish, reflecting weakness in the indicators.

Q: How big is DaVita, Inc.?

As of Jun 18, DaVita, Inc. has a market capitalization of 11,364.46 million, categorizing it as a Mid Cap company.As of Jun 18, the company reported net sales of 12,968.52 million and a net profit of 1,176.98 million for the latest four quarters.As of Dec 24, the balance sheet shows shareholder's funds of 121.12 million and total assets of 17,971.92 million.

Q: What does DaVita, Inc. do?

Overview:DaVita, Inc. operates in the Pharmaceuticals & Biotechnology industry, providing kidney dialysis services for patients suffering from chronic kidney failure, with a market capitalization in the mid-cap bracket.Financial Snapshot:- Most recent Net Sales: 3,224 Million (Quarterly Results - Mar 2025)- Most recent Net Profit: 232 Million (Quarterly Results - Mar 2025)- Market cap: USD 11,364.46 Million (Mid Cap)Key Metrics:- P/E: 10.00- Dividend Yield: 0.00%- Debt Equity: -35.01- Return on Equity: -423.09%- Price to Book: -42.55Contact Details:- Address: 2000 16th St, DENVER CO: 80202-5158- Tel: ['1 310 5362668', '1 310 5362585']- Fax: 1 302 6365454- Website: https://www.davita.com/

Q: Who are in the management team of DaVita, Inc.?

As of March 2022, the management team of DaVita, Inc. includes the following individuals:- Ms. Pamela Arway, who serves as the Independent Chairman of the Board.- Mr. Javier Rodriguez, who is the Chief Executive Officer and a Director.- Mr. Charles Berg, who is a Director.- Mr. Shawn Guertin, who is also a Director.- Ms. Barbara Desoer, who holds the position of Independent Director.- Mr. Paul Diaz, who is an Independent Director.- Mr. John Nehra, who is another Independent Director.In summary, the management team consists of a mix of independent directors and key executives, with Mr. Javier Rodriguez as the CEO.

Results Declared: DaVita, Inc. has declared results on 04 Aug 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

435.66 k

Shareholding (Jun 2026)

FII

9.74%

Held by 322 FIIs

DII

90.21%

Held by 30 DIIs

Promoter

0.04%

Is DaVita, Inc. overvalued or undervalued?

20-Sep-2025

As of May 12, 2025, DaVita, Inc. is considered risky and overvalued with a P/E ratio of 10, an EV to EBITDA ratio of 7.83, and poor performance compared to peers and the S&P 500, indicating a negative investment outlook.

View full answer

Is DaVita, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, DaVita, Inc. exhibits a bearish technical trend, with negative performance indicators and year-to-date returns of -12.92%, significantly underperforming the S&P 500.

View full answer

How big is DaVita, Inc.?

22-Jun-2025

As of Jun 18, DaVita, Inc. has a market capitalization of $11.36 billion, with net sales of $12.97 billion and a net profit of $1.18 billion for the latest four quarters. The balance sheet shows shareholder's funds of $121.12 million and total assets of $17.97 billion.

View full answer

What does DaVita, Inc. do?

22-Jun-2025

DaVita, Inc. provides kidney dialysis services for chronic kidney failure patients and has a market capitalization of approximately $11.36 billion. As of March 2025, it reported net sales of $3.22 billion and a net profit of $232 million.

View full answer

Who are in the management team of DaVita, Inc.?

22-Jun-2025

As of March 2022, DaVita, Inc.'s management team includes CEO Javier Rodriguez and several independent directors, including Pamela Arway (Chair), Charles Berg, Shawn Guertin, Barbara Desoer, Paul Diaz, and John Nehra.

View full answer

Compare DaVita, Inc. with Similar Stocks

Agilon Health, Inc.Encompass Health Corp.Acadia Healthcare Co., Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 2.01% of over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

Negative results in Jun 25

Risky - Negative Book Value

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 11,513 Million (Small Cap)

P/E

11.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-15.25

Return on Equity

-163.56%

Price to Book

-17.68

Revenue and Profits:

Net Sales:

3,554 Million

(Quarterly Results - Jun 2026)

Net Profit:

343 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.36%

6 Months

30.49%

1 Year

43.92%

2 Years

37.16%

3 Years

63.09%

4 Years

114.48%

5 Years

38.0%

DaVita, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.39%

EBIT Growth (5y)

3.61%

EBIT to Interest (avg)

4.56

Debt to EBITDA (avg)

3.65

Net Debt to Equity (avg)

-35.01

Sales to Capital Employed (avg)

1.29

Tax Ratio

18.55%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

17.82%

ROE (avg)

106.77%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-17.68

EV to EBIT

10.67

EV to EBITDA

7.87

EV to Capital Employed

2.31

EV to Sales

1.57

PEG Ratio

2.05

Dividend Yield

ROCE (Latest)

21.67%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 108 Schemes (20.04%)

Foreign Institutions

Held by 322 Foreign Institutions (9.74%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 4.06% vs -5.64% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 24.80% vs -10.13% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,554.10",
          "val2": "3,415.50",
          "chgp": "4.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "738.60",
          "val2": "651.40",
          "chgp": "13.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "146.40",
          "val2": "141.30",
          "chgp": "3.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "343.20",
          "val2": "275.00",
          "chgp": "24.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "160.60%",
          "val2": "138.60%",
          "chgp": "2.20%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.46% vs 5.56% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -15.75% vs 30.69% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "13,643.10",
          "val2": "12,815.50",
          "chgp": "6.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,726.00",
          "val2": "2,678.70",
          "chgp": "1.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "589.90",
          "val2": "412.30",
          "chgp": "43.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-14.20",
          "val2": "89.70",
          "chgp": "-115.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,053.70",
          "val2": "1,250.70",
          "chgp": "-15.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "147.40%",
          "val2": "152.50%",
          "chgp": "-0.51%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ

Jun'26

Mar'26

Change(%)

Net Sales

3,554.10

3,415.50

4.06%

Operating Profit (PBDIT) excl Other Income

738.60

651.40

13.39%

Interest

146.40

141.30

3.61%

Exceptional Items

-2.00

0.00

Consolidate Net Profit

343.20

275.00

24.80%

Operating Profit Margin (Excl OI)

160.60%

138.60%

2.20%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2026 is 4.06% vs -5.64% in Mar 2026

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 24.80% vs -10.13% in Mar 2026

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

13,643.10

12,815.50

6.46%

Operating Profit (PBDIT) excl Other Income

2,726.00

2,678.70

1.77%

Interest

589.90

412.30

43.08%

Exceptional Items

-14.20

89.70

-115.83%

Consolidate Net Profit

1,053.70

1,250.70

-15.75%

Operating Profit Margin (Excl OI)

147.40%

152.50%

-0.51%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 6.46% vs 5.56% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -15.75% vs 30.69% in Dec 2024

All Annual Results

Company CV

About DaVita, Inc.

DaVita, Inc.

Pharmaceuticals & Biotechnology

DaVita Inc., formerly DaVita HealthCare Partners Inc., operates one division: DaVita Kidney Care (Kidney Care). The Kidney Care division consists of the Company's United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. The Company's segments include U.S. dialysis and related lab services and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as an end-stage renal disease (ESRD). In addition, as of March 31, 2019, the Company operated or provided administrative services to 243 outpatient dialysis centers located in nine countries outside of the United States.

Company Coordinates

Company Details

2000 16th St , DENVER CO : 80202-5158

Tel: 1 310 53626681 310 5362585

https://www.davita.com/

Registrar Details